crm 197 Search Results


crm 197 (an inactive diphtheria toxin)  (FUJIFILM)
90
FUJIFILM crm 197 (an inactive diphtheria toxin)
Effects of TAPI-0 and <t>CRM</t> <t>197</t> on sodium orthovanadate (OVA)-induced aortic contraction and phosphorylation of epidermal growth factor receptor (EGFR) and myosin phosphatase target subunit 1 (MYPT1) in rat aortic smooth muscle cells (VSMCs). (A) Contractile force was measured 10 min after treatment with OVA (500 μ mol/L) in rings without endothelium. TAPI-0 (10 μ mol/L) and CRM 197 (10 μ g/mL) were added to the bath 15 min before OVA treatment. The contractile force was expressed as a percentage of the maximal force evoked by 40 mmol/L KCl. Data for rings taken from four animals are expressed as mean ± SE * P < 0.05 vs. OVA alone. (B) Phosphorylated EGFR (Tyr-1173), MYPT1 (Thr-853), and the respective total proteins were measured in VSMCs 10 min after treatment with OVA (500 μ mol/L) by western blotting. TAPI-0 (10 μ mol/L), CRM 197 (10 μ g/mL), or vehicle (Veh; 10 μ L of dimethyl sulfoxide) was added to cultures 15 min before treatment with OVA. Bar graphs represent densitometric quantification of the ratios of phosphorylated to total EGFR and MYPT1. Data are presented as the mean ± SE of four independent experiments. * P < 0.05 vs. Veh; Ψ P < 0.05 vs. OVA alone.
Crm 197 (An Inactive Diphtheria Toxin), supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crm+197/crm+197++an+inactive+diphtheria+toxin+/pmc04184709-19-65-72
Average 90 stars, based on 1 article reviews
crm 197 (an inactive diphtheria toxin) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
crm197  (Sclavo Diagnostics International)
90
Sclavo Diagnostics International crm197
Effects of TAPI-0 and <t>CRM</t> <t>197</t> on sodium orthovanadate (OVA)-induced aortic contraction and phosphorylation of epidermal growth factor receptor (EGFR) and myosin phosphatase target subunit 1 (MYPT1) in rat aortic smooth muscle cells (VSMCs). (A) Contractile force was measured 10 min after treatment with OVA (500 μ mol/L) in rings without endothelium. TAPI-0 (10 μ mol/L) and CRM 197 (10 μ g/mL) were added to the bath 15 min before OVA treatment. The contractile force was expressed as a percentage of the maximal force evoked by 40 mmol/L KCl. Data for rings taken from four animals are expressed as mean ± SE * P < 0.05 vs. OVA alone. (B) Phosphorylated EGFR (Tyr-1173), MYPT1 (Thr-853), and the respective total proteins were measured in VSMCs 10 min after treatment with OVA (500 μ mol/L) by western blotting. TAPI-0 (10 μ mol/L), CRM 197 (10 μ g/mL), or vehicle (Veh; 10 μ L of dimethyl sulfoxide) was added to cultures 15 min before treatment with OVA. Bar graphs represent densitometric quantification of the ratios of phosphorylated to total EGFR and MYPT1. Data are presented as the mean ± SE of four independent experiments. * P < 0.05 vs. Veh; Ψ P < 0.05 vs. OVA alone.
Crm197, supplied by Sclavo Diagnostics International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crm+197/crm+197/10__1002_slash_anie__201506112-21-0-12
Average 90 stars, based on 1 article reviews
crm197 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
19f-crm 197  (Ribi ImmunoChem Research)
90
Ribi ImmunoChem Research 19f-crm 197
Effects of TAPI-0 and <t>CRM</t> <t>197</t> on sodium orthovanadate (OVA)-induced aortic contraction and phosphorylation of epidermal growth factor receptor (EGFR) and myosin phosphatase target subunit 1 (MYPT1) in rat aortic smooth muscle cells (VSMCs). (A) Contractile force was measured 10 min after treatment with OVA (500 μ mol/L) in rings without endothelium. TAPI-0 (10 μ mol/L) and CRM 197 (10 μ g/mL) were added to the bath 15 min before OVA treatment. The contractile force was expressed as a percentage of the maximal force evoked by 40 mmol/L KCl. Data for rings taken from four animals are expressed as mean ± SE * P < 0.05 vs. OVA alone. (B) Phosphorylated EGFR (Tyr-1173), MYPT1 (Thr-853), and the respective total proteins were measured in VSMCs 10 min after treatment with OVA (500 μ mol/L) by western blotting. TAPI-0 (10 μ mol/L), CRM 197 (10 μ g/mL), or vehicle (Veh; 10 μ L of dimethyl sulfoxide) was added to cultures 15 min before treatment with OVA. Bar graphs represent densitometric quantification of the ratios of phosphorylated to total EGFR and MYPT1. Data are presented as the mean ± SE of four independent experiments. * P < 0.05 vs. Veh; Ψ P < 0.05 vs. OVA alone.
19f Crm 197, supplied by Ribi ImmunoChem Research, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crm+197/19f+crm+197/pmc00096820-70-11-20
Average 90 stars, based on 1 article reviews
19f-crm 197 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
dtp-hbv-hib-crm 197 glycoconjugate  (Panacea Biotec)
90
Panacea Biotec dtp-hbv-hib-crm 197 glycoconjugate
Effects of TAPI-0 and <t>CRM</t> <t>197</t> on sodium orthovanadate (OVA)-induced aortic contraction and phosphorylation of epidermal growth factor receptor (EGFR) and myosin phosphatase target subunit 1 (MYPT1) in rat aortic smooth muscle cells (VSMCs). (A) Contractile force was measured 10 min after treatment with OVA (500 μ mol/L) in rings without endothelium. TAPI-0 (10 μ mol/L) and CRM 197 (10 μ g/mL) were added to the bath 15 min before OVA treatment. The contractile force was expressed as a percentage of the maximal force evoked by 40 mmol/L KCl. Data for rings taken from four animals are expressed as mean ± SE * P < 0.05 vs. OVA alone. (B) Phosphorylated EGFR (Tyr-1173), MYPT1 (Thr-853), and the respective total proteins were measured in VSMCs 10 min after treatment with OVA (500 μ mol/L) by western blotting. TAPI-0 (10 μ mol/L), CRM 197 (10 μ g/mL), or vehicle (Veh; 10 μ L of dimethyl sulfoxide) was added to cultures 15 min before treatment with OVA. Bar graphs represent densitometric quantification of the ratios of phosphorylated to total EGFR and MYPT1. Data are presented as the mean ± SE of four independent experiments. * P < 0.05 vs. Veh; Ψ P < 0.05 vs. OVA alone.
Dtp Hbv Hib Crm 197 Glycoconjugate, supplied by Panacea Biotec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crm+197/dtp+hbv+hib+crm+197+glycoconjugate/pmc07152242-133-12-0
Average 90 stars, based on 1 article reviews
dtp-hbv-hib-crm 197 glycoconjugate - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
crm-197  (Federation of European Neuroscience Societies)
90
Federation of European Neuroscience Societies crm-197
Effects of TAPI-0 and <t>CRM</t> <t>197</t> on sodium orthovanadate (OVA)-induced aortic contraction and phosphorylation of epidermal growth factor receptor (EGFR) and myosin phosphatase target subunit 1 (MYPT1) in rat aortic smooth muscle cells (VSMCs). (A) Contractile force was measured 10 min after treatment with OVA (500 μ mol/L) in rings without endothelium. TAPI-0 (10 μ mol/L) and CRM 197 (10 μ g/mL) were added to the bath 15 min before OVA treatment. The contractile force was expressed as a percentage of the maximal force evoked by 40 mmol/L KCl. Data for rings taken from four animals are expressed as mean ± SE * P < 0.05 vs. OVA alone. (B) Phosphorylated EGFR (Tyr-1173), MYPT1 (Thr-853), and the respective total proteins were measured in VSMCs 10 min after treatment with OVA (500 μ mol/L) by western blotting. TAPI-0 (10 μ mol/L), CRM 197 (10 μ g/mL), or vehicle (Veh; 10 μ L of dimethyl sulfoxide) was added to cultures 15 min before treatment with OVA. Bar graphs represent densitometric quantification of the ratios of phosphorylated to total EGFR and MYPT1. Data are presented as the mean ± SE of four independent experiments. * P < 0.05 vs. Veh; Ψ P < 0.05 vs. OVA alone.
Crm 197, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crm+197/crm+197/pm09637258-8-11-21
Average 90 stars, based on 1 article reviews
crm-197 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
menacwy crm 197 vaccine  (Novartis)
86
Novartis menacwy crm 197 vaccine
Effects of TAPI-0 and <t>CRM</t> <t>197</t> on sodium orthovanadate (OVA)-induced aortic contraction and phosphorylation of epidermal growth factor receptor (EGFR) and myosin phosphatase target subunit 1 (MYPT1) in rat aortic smooth muscle cells (VSMCs). (A) Contractile force was measured 10 min after treatment with OVA (500 μ mol/L) in rings without endothelium. TAPI-0 (10 μ mol/L) and CRM 197 (10 μ g/mL) were added to the bath 15 min before OVA treatment. The contractile force was expressed as a percentage of the maximal force evoked by 40 mmol/L KCl. Data for rings taken from four animals are expressed as mean ± SE * P < 0.05 vs. OVA alone. (B) Phosphorylated EGFR (Tyr-1173), MYPT1 (Thr-853), and the respective total proteins were measured in VSMCs 10 min after treatment with OVA (500 μ mol/L) by western blotting. TAPI-0 (10 μ mol/L), CRM 197 (10 μ g/mL), or vehicle (Veh; 10 μ L of dimethyl sulfoxide) was added to cultures 15 min before treatment with OVA. Bar graphs represent densitometric quantification of the ratios of phosphorylated to total EGFR and MYPT1. Data are presented as the mean ± SE of four independent experiments. * P < 0.05 vs. Veh; Ψ P < 0.05 vs. OVA alone.
Menacwy Crm 197 Vaccine, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crm+197/197+crm+diphtheria+mutant+toxin/10__1097_slash_inf__0b013e318292f425-46-22-26
Average 86 stars, based on 1 article reviews
menacwy crm 197 vaccine - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
pneumococcal conjugate vaccine pn1 crm 197  (Serum Institute India)
86
Serum Institute India pneumococcal conjugate vaccine pn1 crm 197
Effects of TAPI-0 and <t>CRM</t> <t>197</t> on sodium orthovanadate (OVA)-induced aortic contraction and phosphorylation of epidermal growth factor receptor (EGFR) and myosin phosphatase target subunit 1 (MYPT1) in rat aortic smooth muscle cells (VSMCs). (A) Contractile force was measured 10 min after treatment with OVA (500 μ mol/L) in rings without endothelium. TAPI-0 (10 μ mol/L) and CRM 197 (10 μ g/mL) were added to the bath 15 min before OVA treatment. The contractile force was expressed as a percentage of the maximal force evoked by 40 mmol/L KCl. Data for rings taken from four animals are expressed as mean ± SE * P < 0.05 vs. OVA alone. (B) Phosphorylated EGFR (Tyr-1173), MYPT1 (Thr-853), and the respective total proteins were measured in VSMCs 10 min after treatment with OVA (500 μ mol/L) by western blotting. TAPI-0 (10 μ mol/L), CRM 197 (10 μ g/mL), or vehicle (Veh; 10 μ L of dimethyl sulfoxide) was added to cultures 15 min before treatment with OVA. Bar graphs represent densitometric quantification of the ratios of phosphorylated to total EGFR and MYPT1. Data are presented as the mean ± SE of four independent experiments. * P < 0.05 vs. Veh; Ψ P < 0.05 vs. OVA alone.
Pneumococcal Conjugate Vaccine Pn1 Crm 197, supplied by Serum Institute India, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crm+197/197+conjugate+crm+pn1+pneumococcal+vaccine/pmc12367788-45-1-10
Average 86 stars, based on 1 article reviews
pneumococcal conjugate vaccine pn1 crm 197 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


Effects of TAPI-0 and CRM 197 on sodium orthovanadate (OVA)-induced aortic contraction and phosphorylation of epidermal growth factor receptor (EGFR) and myosin phosphatase target subunit 1 (MYPT1) in rat aortic smooth muscle cells (VSMCs). (A) Contractile force was measured 10 min after treatment with OVA (500 μ mol/L) in rings without endothelium. TAPI-0 (10 μ mol/L) and CRM 197 (10 μ g/mL) were added to the bath 15 min before OVA treatment. The contractile force was expressed as a percentage of the maximal force evoked by 40 mmol/L KCl. Data for rings taken from four animals are expressed as mean ± SE * P < 0.05 vs. OVA alone. (B) Phosphorylated EGFR (Tyr-1173), MYPT1 (Thr-853), and the respective total proteins were measured in VSMCs 10 min after treatment with OVA (500 μ mol/L) by western blotting. TAPI-0 (10 μ mol/L), CRM 197 (10 μ g/mL), or vehicle (Veh; 10 μ L of dimethyl sulfoxide) was added to cultures 15 min before treatment with OVA. Bar graphs represent densitometric quantification of the ratios of phosphorylated to total EGFR and MYPT1. Data are presented as the mean ± SE of four independent experiments. * P < 0.05 vs. Veh; Ψ P < 0.05 vs. OVA alone.

Journal: Pharmacology Research & Perspectives

Article Title: Orthovanadate-induced vasocontraction is mediated by the activation of Rho-kinase through Src-dependent transactivation of epidermal growth factor receptor

doi: 10.1002/prp2.39

Figure Lengend Snippet: Effects of TAPI-0 and CRM 197 on sodium orthovanadate (OVA)-induced aortic contraction and phosphorylation of epidermal growth factor receptor (EGFR) and myosin phosphatase target subunit 1 (MYPT1) in rat aortic smooth muscle cells (VSMCs). (A) Contractile force was measured 10 min after treatment with OVA (500 μ mol/L) in rings without endothelium. TAPI-0 (10 μ mol/L) and CRM 197 (10 μ g/mL) were added to the bath 15 min before OVA treatment. The contractile force was expressed as a percentage of the maximal force evoked by 40 mmol/L KCl. Data for rings taken from four animals are expressed as mean ± SE * P < 0.05 vs. OVA alone. (B) Phosphorylated EGFR (Tyr-1173), MYPT1 (Thr-853), and the respective total proteins were measured in VSMCs 10 min after treatment with OVA (500 μ mol/L) by western blotting. TAPI-0 (10 μ mol/L), CRM 197 (10 μ g/mL), or vehicle (Veh; 10 μ L of dimethyl sulfoxide) was added to cultures 15 min before treatment with OVA. Bar graphs represent densitometric quantification of the ratios of phosphorylated to total EGFR and MYPT1. Data are presented as the mean ± SE of four independent experiments. * P < 0.05 vs. Veh; Ψ P < 0.05 vs. OVA alone.

Article Snippet: The following inhibitors were purchased from the commercial sources indicated: AG1478 [4-(3-chloroanilino)-6,7-dimethoxyquinazoline], EGFR inhibitor 1 [cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide], hydroxyfasudil [1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine], ML-7 [1-(5-iodonaphthalene-1-sulfonyl)homopiperazine], PP2 {[4-amino-3-(4-chlorophenyl)-1-( t -butyl)-1 H -pyrazolo[3,4-d]pyrimidine}, PTP-I, TAPI-0 { N -( R )-[2-(hydroxyaminocarbonyl) methyl]-4-methylpentanoyl- l -naphthylalanyl- l -alanine amide}, and Y-27632 { R -[+]-trans- N -[4-pyridyl]-4-[1-aminoethyl]-cyclohexanecarboxamide} from Merck-Millipore (Tokyo, Japan); Src inhibitor No. 5 {5 [4-(3′-methoxy-6′-chloro-anilino)-6-methoxy-7(morpholino-3-propoxy)-quinazoline]} from Biaffin GmbH & Co KG (Kassel, Germany); CRM 197 (an inactive diphtheria toxin) from WAKO (Osaka, Japan); OVA from Nakarai Tesque (Kyoto, Japan).

Techniques: Western Blot